## LISTING OF CLAIMS

1. (Currently Amended) A pharmaceutical composition comprising:

an effective amount of amlodipine;

an effective amount of a substantially pure form of hydroxylated atorvastatin metabolite; and

a pharmaceutically acceptable carrier or diluent,

wherein said hydroxylated atorvastatin metabolite is selected from the group consisting of ~~ortho-hydroxylated, meta-hydroxylated and para-hydroxylated atorvastatin metabolite~~ (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(4-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(3-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, and (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(2-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, and wherein the effective amounts of amlodipine and hydroxylated atorvastatin metabolite synergistically inhibit lipid peroxidation in human low density lipoprotein or lipid membrane to achieve a therapeutic effect.

2. (Canceled)

3. (Currently Amended) The pharmaceutical composition of claim ~~2~~1 wherein ~~the therapeutically effective derivative of~~ said amlodipine comprises amlodipine besylate.

4. (Previously Presented) The pharmaceutical composition of claim 1 wherein said amounts of amlodipine and hydroxylated atorvastatin metabolite are coordinated to synergistically inhibit lipid peroxidation to the extent necessary to achieve the therapeutic effect of reducing the risk of arterial and related heart disease.

5. (Original) The pharmaceutical composition of claim 4 wherein said arterial and related heart disease is selected from the group consisting of hypertension, hyperlipidemia, atherosclerosis, arteriosclerosis, coronary artery disease, myocardial infarction, congestive heart failure, stroke, and angina pectoris.

6. (Previously Presented) The pharmaceutical composition of claim 1 wherein said amounts of amlodipine and hydroxylated atorvastatin metabolite are coordinated to synergistically inhibit lipid peroxidation.

7.- 28. (Canceled)

29. (Withdrawn) A method of treating arterial and related heart disease and substantially inhibit lipid peroxide in LDL and lipid membranes comprising administering a therapeutically effective amount of a combination of amlodipine and hydroxylated atorvastatin metabolite.

30. (Withdrawn) The method of claim 29 wherein amlodipine comprises an effective derivative of amlodipine.

31. (Withdrawn) The method of claim 30 wherein the therapeutically effective derivative of amlodipine comprises amlodipine besylate.

32. (Withdrawn) The method of claim 29 wherein said arterial and related heart disease is selected from the group consisting of hypertension, hyperlipidemia, atherosclerosis, arteriosclerosis, coronary artery disease, myocardial infarction, congestive heart failure, stroke, and angina pectoris.

33. (Withdrawn) The method of claim 29 wherein amlodipine and atorvastatin metabolite are administered in the same therapeutic.

34. (Withdrawn) The method of claim 29 wherein amlodipine and atorvastatin metabolite are administered as separate therapeutics.

35. (Withdrawn) The method of claim 29 wherein amlodipine and the atorvastatin metabolite are administered at the same time.

36. (Withdrawn) The method of claims 29 wherein amlodipine and the atorvastatin metabolite are administered at different times.

37. (Withdrawn) A method of substantially inhibiting lipid oxidation and lowering blood pressure and systemic lipid concentrations comprising administering a therapeutically effective amount for such purposes of a combination of amlodipine and o-hydroxylated atorvastatin metabolite.

38. (Withdrawn) The method of claim 37 wherein amlodipine comprises a therapeutically effective derivative of amlodipine.

39. (Withdrawn) The method of claim 38 wherein the therapeutically effective derivative of amlodipine comprises amlodipine besylate.

40. (Withdrawn) The method of claim 37 wherein amlodipine and the atorvastatin metabolite are administered in the same therapeutic.

41. (Withdrawn) The method of claim 37 wherein amlodipine and the atorvastatin metabolite are administered as separate therapeutics.

42. (Withdrawn) The method of claim 37 wherein amlodipine and the atorvastatin metabolite are administered at the same time.

43. (Withdrawn) The method of claim 37 wherein amlodipine and the atorvastatin metabolite are administered at different times.

44. (Withdrawn) The method of claim 37 wherein said pharmaceutical composition lowers blood pressure and systemic lipid concentrations to a level consistent with a reduced risk of arterial and related heart disease.

45. (Withdrawn) The method of claim 37 wherein said arterial and related heart disease is selected from the group consisting of hypertension, hyperlipidemia,

atherosclerosis, arteriosclerosis, coronary artery disease, myocardial infarction, congestive heart failure, stroke, and angina pectoris.

46. (Withdrawn) The method of claim 37 wherein said pharmaceutical composition lowers blood pressure and systemic lipid concentrations to a level statistically equivalent to normal.

47. (Withdrawn) The method of claims 37-46 wherein the lowering of blood pressure and systemic lipid concentrations results at least partially from reduced lipid oxidation.

48. (Withdrawn) A method of synergistically inhibiting lipid oxidation comprising administering a therapeutically effective amount of a combination of amlodipine and hydroxylated atorvastatin metabolite.

49. (Withdrawn) The method of claim 48 wherein amlodipine comprises a therapeutically effective derivative of amlodipine.

50. (Withdrawn) The method of claim 49 wherein the therapeutically effective derivative of amlodipine comprises amlodipine besylate.

51. (Withdrawn) The method of claim 48 wherein amlodipine and the atorvastatin metabolite are administered in the same therapeutic.

52. (Withdrawn) The method of claim 48 wherein amlodipine and the atorvastatin metabolite are administered as separate therapeutics.

53. (Withdrawn) The method of claim 48 wherein amlodipine and the atorvastatin metabolite are administered at the same time.

54. (Withdrawn) The method of claim 48 wherein amlodipine and the atorvastatin metabolite are administered at different times.

55. (Withdrawn) The method of claim 48 wherein said pharmaceutical composition inhibits lipid oxidation to an extent consistent with a reduced risk of arterial and related heart disease.

56. (Withdrawn) The method of claim 55 wherein said arterial and related heart disease is selected from the group consisting of hypertension, hyperlipidemia, atherosclerosis, arteriosclerosis, coronary artery disease, myocardial infarction, congestive heart failure, stroke, and angina pectoris.

57.-59. (Canceled)

60. (Withdrawn) A method of lowering blood pressure and systemic lipid concentrations comprising administering a therapeutically effective amount of combination of amlodipine and hydroxylated atorvastatin metabolite.

61. (Withdrawn) The method of claim 60 wherein said pharmaceutical composition synergistically lowers blood pressure and systemic lipid concentrations to a level statistically equivalent to normal.

62. (Withdrawn) The method of claim 61 wherein the synergistic lowering of blood pressure and systemic lipid concentrations results at least partially from reduced lipid oxidation.

63. (Currently Amended) A pharmaceutical composition comprising:

an effective amount of amlodipine;

an effective amount of a substantially pure form of hydroxylated atorvastatin metabolite; and

a pharmaceutically acceptable carrier or diluent;

wherein said hydroxylated atorvastatin metabolite is selected from the group consisting of ~~ortho-hydroxylated, meta-hydroxylated and para-hydroxylated atorvastatin metabolite~~ (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(4-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(3-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, and (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(2-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, and wherein said effective amounts of amlodipine and hydroxylated atorvastatin metabolite are selected such that a synergistic antioxidant effect is achieved.

64. (Currently Amended) A pharmaceutical composition comprising:

an effective amount of amlodipine;

an effective amount of a substantially pure form of hydroxylated atorvastatin metabolite; and

a pharmaceutically acceptable carrier or diluent;

wherein said hydroxylated atorvastatin metabolite is selected from the group consisting of ~~ortho-hydroxylated, meta-hydroxylated and para-hydroxylated atorvastatin metabolite~~ (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(4-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(3-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, and (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(2-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, and wherein said effective amounts of amlodipine and hydroxylated atorvastatin metabolite are selected such that a synergistic inhibition of lipid peroxidation is achieved.

65. (Previously Presented) The pharmaceutical composition of claim 64 wherein said selection is further coordinated for achieving a synergistic antioxidant effect.

66. (Previously Presented) The pharmaceutical composition of claim 63, wherein said composition is used to treat atherosclerosis.

67. (Previously Presented) The pharmaceutical composition of claim 66, wherein said atherosclerosis involves diseases selected from the group consisting of myocardial infarction, stroke, transient ischemic attack, coronary heart disease and a combination thereof.

68. (Currently Amended) The pharmaceutical composition of claim 63 further comprising an effective amount of ~~endogenous and/or exogenous~~ a lipophilic antioxidant.